-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
-
Summary
-
RIGEL PHARMACEUTICALS INC quarterly/annual Net Income (Loss) Attributable to Parent history and change rate from 2019 to Q3 2025.
- RIGEL PHARMACEUTICALS INC Net Income (Loss) Attributable to Parent for the quarter ending 30 Sep 2025 was $27.9M, a 125% increase year-over-year.
- RIGEL PHARMACEUTICALS INC Net Income (Loss) Attributable to Parent for the twelve months ending 30 Sep 2025 was $113M, a 2819% increase year-over-year.
- RIGEL PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2024 was $17.5M.
- RIGEL PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2023 was -$25.1M, a 57.2% increase from 2022.
- RIGEL PHARMACEUTICALS INC annual Net Income (Loss) Attributable to Parent for 2022 was -$58.6M, a 227% decline from 2021.
Net Income (Loss) Attributable to Parent, Trailing 12 Months (USD)
Net Income (Loss) Attributable to Parent, Quarterly (USD)
Net Income (Loss) Attributable to Parent, YoY Quarterly Change (%)
Net Income (Loss) Attributable to Parent, Annual (USD)
Net Income (Loss) Attributable to Parent, YoY Annual Change (%)